Propofol Inhibits In Vitro Platelet Aggregation in Human Whole Blood
J.P. De La Cruz, José Antonio Llamas Carmona, M. V. Paez, Encarnación Blanco‐Reina, Felipe Sánchez de la Cuesta
Abstract
J.P. De La Cruz, José Antonio Llamas Carmona, M. V. Paez, Encarnación Blanco‐Reina, Felipe Sánchez de la Cuesta
Abstract
To help clarify the mechanism of propofol-induced vasodilation, we investigated whether propofol, at concentrations ranging from 10(-6) to 10(-3) M, inhibited platelet aggregation in human whole blood. Propofol inhibited platelet aggregation induced by adenosine diphosphate, collagen, or arachidonic acid in a concentration-dependent manner, with a 50% inhibited concentration (micromol/L) of 136 +/- 9.8 for adenosine diphosphate, 77.8 +/- 6.6 for collagen, and 71.8 +/- 5.4 for arachidonic acid. In platelet-rich plasma, propofol had no significant antiaggregant effect except when arachidonic acid was used as the aggregant (50% inhibited concentration 105 +/- 9.9 micromol/L). The antiaggregant effect of propofol in platelet-rich plasma was increased in the presence of red blood cells or leukocytes in a cell number-dependent manner. We conclude that propofol reduces the platelet activity in human whole blood in vitro.
OpenAlex reports 37 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To help clarify the mechanism of propofol-induced vasodilation, we investigated whether propofol, at concentrations ranging from 10(-6) to 10(-3) M, inhibited platelet aggregation in human whole blood. Propofol inhibited platelet aggregation induced by adenosine diphosphate, collagen, or arachidonic acid in a concentration-dependent manner, with a 50% inhibited concentration (micromol/L) of 136 +/- 9.8 for adenosine diphosphate, 77.8 +/- 6.6 for collagen, and 71.8 +/- 5.4 for arachidonic acid. In platelet-rich plasma, propofol had no significant antiaggregant effect except when arachidonic acid was used as the aggregant (50% inhibited concentration 105 +/- 9.9 micromol/L). The antiaggregant effect of propofol in platelet-rich plasma was increased in the presence of red blood cells or leukocytes in a cell number-dependent manner. We conclude that propofol reduces the platelet activity in human whole blood in vitro.
Key concepts: Arachidonic acid, Propofol, Platelet, Adenosine diphosphate, Medicine, In vitro, Whole blood, Adenosine